BioLineRxが米国預託証券およびワラントの引受公募で1540万ドル調達見込みと発表
BioLineRxが米国預託証券およびワラントの引受公募で1540万ドル調達見込みと発表
AsiaNet 77350 (0189)
【テルアビブ(イスラエル)2019年2月6日PR Newswire=共同通信JBN】腫瘍学と免疫学に重点を置いた臨床段階のバイオ医薬品会社であるBioLineRx Ltd.(NASDAQ/TASE: BLRX)は6日、それぞれが普通株1株を表す2800万株の米国預託証券(ADS)および2800万株のADSを購入するワラントの引受公募で、公募価格をADSおよび付随するワラント当たり0.55ドルに値付けしたと発表した。ワラントは即時行使可能で、発効日から5年で失効し、行使価格はADS当たり0.75ドルとなる。公募による総調達資金額は、引受け割引および手数料ならびにBioLineRxが支払う予定の公募費用の控除前で、ワラント行使を除いた場合、1540万ドルと予想される。この公募に含まれるすべての有価証券はBioLineRxにより売却される。売出し完了は、慣例的な終了条件によるが、2019年2月7日またはその前後となる見込み。 BioLineRxは、公募からの純調達資金を、運転資金や臨床試験資金を含む可能性があるが、これに限らない一般的な企業目的に使用することを見込んでいる。
Oppenheimer & Co. Inc. が今回の公募の唯一の売り出し幹事を務めた。Maxim Group LLCが公募の共同幹事を務めた。
上述の証券は、証券取引委員会(SEC)に提出し、有効と宣言された発行登録書(File No. 333-222332)に従って発行される。当該募集に関連する仮目論見書の補足は2019年2月4日SECに提出され、SECのウェブサイトwww.sec.gov で入手可能になっている。当該募集に関連する最終目論見書の補足はSECに提出され、SECのウェブサイトwww.sec.gov で入手可能となる。最終目論見書の補足のコピーは入手可能になれば、以下から取得することもできる:
Oppenheimer & Co. Inc.
Syndicate Prospectus Department
85 Broad Street, 26th Floor
New York, New York 10004
電話 212-667-8055
電子メール EquityProspectus@opco.com
このプレスリリースは、販売申し出や、購入申し出の勧誘に当たるものではなく、また、州もしくは司法管轄地域の証券取引法に基づく登録や承認の以前のそのような申し出、勧誘、販売が違法である州や地域においては、これら証券の販売を行ってはならない。
▽BioLineRxについて
BioLineRxは腫瘍学と免疫学に重点を置いた臨床段階のバイオ医薬品会社である。同社は新規化合物をインライセンスし、それらを前臨床段階および/または臨床段階を通して開発し、そして次に高度な臨床開発および/または商品化のために製薬会社と提携する。
BioLineRxの主な治療薬候補は以下の通り:
*BL-8040:がん治療プラットフォームで、再発/難治性急性骨髄性白血病(AML)の第2a相試験を成功裏に完了し、AML強化治療として第2b相試験の最中で、自家移植のための幹細胞動員に関する第3相試験を開始した。
*AGI-134:多発性固形腫瘍に対して開発中の免疫療法治療薬で、最近、第1/2a相試験を開始した。
BioLineRxはさらに、イスラエル発の特定の新薬候補共同開発のためのノバルティスとの戦略提携、BL-8040とKEYTRUDA(R)(pembrolizumab)の併用を用いて膵臓がんで第2a相試験を実施するMSD(米国およびカナダではメルクとして知られている)との協力契約、および、ロシュグループの一員であるジェネンテックとの間で、複数の固形腫瘍症状およびAMLに関するいくつかの第1b/2相試験においてBL-8040とジェネンテックのatezolizumabの併用を調査する協力契約をそれぞれ結んでいる。
ソース:BioLineRx Ltd.
▽問い合わせ先
Tim McCarthy
LifeSci Advisors, LLC
+1-212-915-2564
tim@lifesciadvisors.com
Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipihai5@gmail.com
BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
PR77350
TEL AVIV, Israel, Feb. 6, 2019 /PRNewswire=KYODO JBN/ --
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company
focused on oncology and immunology, today announced that it has priced an
underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"),
each representing one of its ordinary shares, and warrants to purchase
28,000,000 ADSs, at a public offering price of $0.55 per ADS and accompanying
warrant. The warrants will be exercisable immediately, will expire five years
from the date of issuance and will have an exercise price of $0.75 per ADS. The
gross proceeds of the offering to the Company are expected to be $15.4 million,
before deducting underwriting discounts and commissions and estimated offering
expenses payable by BioLineRx, and excluding the exercise of any warrants. All
of the securities in the offering are to be sold by BioLineRx. The closing of
the offering is expected to occur on or about February 7, 2019, subject to
customary closing conditions. BioLineRx anticipates using the net proceeds from
the offering for general corporate purposes, which may include, but are not
limited to, working capital and funding clinical trials.
Oppenheimer & Co. Inc. acted as sole book-running manager for the offering.
Maxim Group LLC acted as co-manager for the offering.
The securities described above will be issued pursuant to a shelf registration
statement (File No. 333-222332) that was previously filed with, and declared
effective by, the Securities and Exchange Commission ("SEC"). A preliminary
prospectus supplement related to the offering was filed with the SEC on
February 4, 2019 and is available on the SEC's website located at www.sec.gov.
The final prospectus supplement related to the offering will be filed with the
SEC and will be available on the SEC's website located at www.sec.gov. Copies
of the final prospectus supplement may also be obtained, when available, from
Oppenheimer & Co. Inc., 85 Broad St., 26th Floor, New York, New York 10004,
Attention: Syndicate Prospectus Department, or by telephone: (212) 667-8055 or
by email: EquityProspectus@opco.com.
This press release does not constitute an offer to sell or a solicitation of an
offer to buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or
jurisdiction.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology.
The Company in-licenses novel compounds, develops them through pre-clinical
and/or clinical stages, and then partners with pharmaceutical companies for
advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy
platform, which has successfully completed a Phase 2a study for
relapsed/refractory acute myeloid leukemia ("AML") and is in the midst of a
Phase 2b study as an AML consolidation treatment and has initiated a Phase 3
study in stem cell mobilization for autologous transplantation; and AGI-134, an
immunotherapy treatment in development for multiple solid tumors, which has
recently initiated a Phase 1/2a study. In addition, BioLineRx has a strategic
collaboration with Novartis for the co-development of selected Israeli-sourced
novel drug candidates; a collaboration agreement with MSD (known as Merck in
the United States and Canada), on the basis of which the Company is conducting
a Phase 2a study in pancreatic cancer using the combination of BL-8040 and
KEYTRUDA(R)(pembrolizumab), and a collaboration agreement with Genentech Inc.,
a member of the Roche Group, to investigate the combination of BL-8040 and
Genentech's atezolizumab in several Phase 1b/2 studies for multiple solid tumor
indications and AML.
Various statements in this release concerning BioLineRx's future expectations
constitute "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements include words such
as "may," "expects," "anticipates," "believes," and "intends," and describe
opinions about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual results,
performance or achievements of BioLineRx to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Some of these risks are: changes in relationships
with collaborators; the impact of competitive products and technological
changes; risks relating to the development of new products; and the ability to
implement technological improvements. These and other factors are more fully
discussed in the "Risk Factors" section of BioLineRx's most recent annual
report on Form 20-F filed with the Securities and Exchange Commission on March
6, 2018 and BioLineRx's other filings with the Securities and Exchange
Commission. In addition, any forward-looking statements represent BioLineRx's
views only as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. BioLineRx does not assume any
obligation to update any forward-looking statements unless required by law.
SOURCE BioLineRx Ltd.
CONTACT: Tim McCarthy, LifeSci Advisors, LLC, +1-212-915-2564,
tim@lifesciadvisors.com; Tsipi Haitovsky, Public Relations, +972-52-598-9892,
tsipihai5@gmail.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。